Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

for patients with advanced clear cell renal cell carcinoma (RCC), according to the latest data from the phase 3 LITESPARK-003 (NCT03634540) study. 1 The results were presented at the 2025 American ...